← Back to Search

CAR T-cell Therapy

CD30 CAR T-Cells for Testicular Cancer

Phase 2
Recruiting
Led By Matthew I Milowsky
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years at the time of consent.
Histologically confirmed diagnosis of Nonseminomatous Germ Cell Tumors (NSGCT) of any primary site.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is researching a new way to treat Non-Seminomatous Germ Cell Tumors (NSGCT) by combining antibodies and T cells, which may help to improve treatment options for future cancer patients.

Who is the study for?
Adults over 18 with Nonseminomatous Germ Cell Tumors (NSGCT) who've had at least one prior treatment can join. They must show tumor growth or elevated cancer markers after high-dose chemo. Pregnant women, those breastfeeding, and individuals with active HIV, HTLV, hepatitis B or C are excluded.Check my eligibility
What is being tested?
The trial is testing ATLCAR.CD30 Cells combined with Cyclophosphamide and Fludarabine in patients with NSGCT. It's a phase 2 study to see if modified T cells from the patient's blood can fight cancer more effectively when combined with antibodies.See study design
What are the potential side effects?
Potential side effects may include immune reactions due to modified T cells attacking the body’s own tissues, as well as typical chemotherapy-related issues like nausea, fatigue, hair loss, and increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My cancer is a type of germ cell tumor that is not seminoma.
Select...
I have had at least one treatment for my non-seminoma germ cell tumor.
Select...
My cancer has returned or worsened after strong chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Overall response rate (ORR)- Response Evaluation Criteria In Solid Tumors Criteria (RECIST)
Secondary outcome measures
Adverse Events CTCAE
Cytokine Release Syndrome (CRS)
Duration of response (DOR)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ATLCAR.CD30Experimental Treatment3 Interventions
Single Group Assignment: Subjects with Nonseminomatous Germ Cell Tumors who meet eligibility criteria for cellular therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
2012
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,153 Total Patients Enrolled
University Cancer Research Fund at Lineberger Comprehensive Cancer CenterUNKNOWN
3 Previous Clinical Trials
110 Total Patients Enrolled
Matthew I MilowskyPrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Media Library

ATLCAR.CD30 Cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05634785 — Phase 2
Germ Cell Tumors Research Study Groups: ATLCAR.CD30
Germ Cell Tumors Clinical Trial 2023: ATLCAR.CD30 Cells Highlights & Side Effects. Trial Name: NCT05634785 — Phase 2
ATLCAR.CD30 Cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05634785 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment process for this research still open?

"Clinicaltrials.gov reveals that recruitment for this research trial is still ongoing, with the original posting being on December 9th 2022 and subsequent updates occurring just 4 days later."

Answered by AI

What is the current recruitment quota for this clinical trial?

"Affirmative. Clinicaltrials.gov attests that this clinical examination is presently enrolling volunteers; it was first advertised on December 9th 2022 and the listing had its last update on December 13th 2022. 18 patients are needed at a single medical centre for this trial to move forward."

Answered by AI

What risks do individuals face when exposed to ATLCAR.CD30?

"Our evaluation unit at Power assigned ATLCAR.CD30 a safety score of 2, due to the evidence from Phase 2 trials that suggest its security; however, there is no research verifying its efficacy."

Answered by AI
~12 spots leftby Dec 2026